Clinical trial
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Sutimlimab in Patients With Primary Cold Agglutinin Disease Without a Recent History of Blood Transfusion
NCT03347422 is registered in ClinicalTrials.gov with Bioverativ, a Sanofi company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Sutimlimab in Patients With Primary Cold Agglutinin Disease Without a Recent History of Blood Transfusion
- Lead sponsor
- Bioverativ, a Sanofi company
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- March 17, 2018
- Completion date
- December 3, 2021
- Enrollment
- 42 (actual)
- Sites
- 53
Conditions
As the registry lists them; a condition with its own page is linked.
cold agglutinin disease